Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Hilleman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmacotherapy|September 29, 2011
Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic reviewDaniel Hilleman, Jennifer Campbell
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant peptides in thrombolysisJennifer Campbell, Daniel Hilleman
Pharmacotherapy|May 2, 2008
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemiaStephanie Maciejewski, Daniel Hilleman
Managed Care (Langhorne, Pa.)|February 18, 2016
Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not InterchangeableDaniel Hilleman, Aiman Smer
Journal of Asthma and Allergy|March 26, 2011
Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasoneRobyn Teply, Jennifer Campbell, Daniel Hilleman
Cardiology Research|March 30, 2017
A Review of Currently Available Fenofibrate and Fenofibric Acid FormulationsHua Ling, John T Luoma, Daniel Hilleman
Lipids in Health and Disease|July 23, 2016
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaJames Backes, Deborah Anzalone, Daniel Hilleman, et al.
Pharmacotherapy|April 7, 2022
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize careBarbara S Wiggins, James M Backes, Daniel Hilleman
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 5, 2021
Management of patients with fibrosing interstitial lung diseasesLee E Morrow, Daniel Hilleman, Mark A Malesker
Clinical Therapeutics|September 28, 2023
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering AgentsMegan Hiles, Ashley Simmons, Daniel Hilleman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmacotherapy|September 29, 2011
Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic reviewDaniel Hilleman, Jennifer Campbell
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant peptides in thrombolysisJennifer Campbell, Daniel Hilleman
Pharmacotherapy|May 2, 2008
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemiaStephanie Maciejewski, Daniel Hilleman
Managed Care (Langhorne, Pa.)|February 18, 2016
Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not InterchangeableDaniel Hilleman, Aiman Smer
Journal of Asthma and Allergy|March 26, 2011
Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasoneRobyn Teply, Jennifer Campbell, Daniel Hilleman
Cardiology Research|March 30, 2017
A Review of Currently Available Fenofibrate and Fenofibric Acid FormulationsHua Ling, John T Luoma, Daniel Hilleman
Lipids in Health and Disease|July 23, 2016
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaJames Backes, Deborah Anzalone, Daniel Hilleman, et al.
Pharmacotherapy|April 7, 2022
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize careBarbara S Wiggins, James M Backes, Daniel Hilleman
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 5, 2021
Management of patients with fibrosing interstitial lung diseasesLee E Morrow, Daniel Hilleman, Mark A Malesker
Clinical Therapeutics|September 28, 2023
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering AgentsMegan Hiles, Ashley Simmons, Daniel Hilleman, et al.
Pageof 2